Join the Asia-Australia success stories

Orthocell confirms $4 million capital raise

Regenerative medicine company Orthocell (ASX:OCC) has secured commitments from new and existing professional and sophisticated investors in Australia and Hong Kong to raise $4 million. 

Read the article Orthocell confirms $4 million capital raise from Biotech Dispatch.

SUDA and Eddingpharm

Australian drug delivery company SUDA and Chinese pharmaceutical company Eddingpharm have entered into an exclusive license agreement, including an upfront cash payment of approximately AU$400,000.

Read SUDA’s media release, SUDA LTD and Eddingpharm enter licensing agreement for ZolpiMistTM in China.


Chinese genome sequencing company BGI, one of the largest companies in the world of its kind, will use Queensland’s QIMR Berghofer Medical Research Institute as its headquarters for the Asia-Pacific Region.

Read the article Global genomics giant establishes base at QIMR Berghofer from QIMR Berghofer Medical Research Institute.

Griffith University’s Institute of Glycomics and Olymvax Biopharmaceuticals

Griffith University have signed a collaborative and license agreement with Olymvax to discover, develop and commercialise its Group A Streptococcus (GAS) vaccine technology exclusively for Greater China.

Read the article Strep A vaccine partnership raises hope for millions from Griffith News.

China Resources and GenesisCare

China Resources acquired a major stake in Australian provider of radiation oncology and cardiology services GenesisCare, which is valued at $1.3 billion.

Read the article A week in review: Cross-border investments rule the news from Seeking Alpha.

Healthe Care and China’s Luye Medical Group

Healthe Care, one of Australia’s largest private hospital operators, has received $938 million in a sale to China’s Luye Medical Group, part of the multibillion-dollar privately owned Luye Group. This sale will help build healthcare services in Australia, China and in many other countries in Asia.

Read the article Healthe Care sold to China's Luye Medical from the Sydney Morning Herald.

Cynata Therapeutics and Regience K.K.

Regience K.K., Japanese regenerative medicine venture company, signed an agreement to investment AU$250,000 in Cynata Therapeutics, Australian stem cell and regenerative medicine company early in 2016.

Read the article, Cynata Therapeutics and Japan’s Regience K.K. in stem cell alliance, from Proactive Investors Australia, or the ASX Announcement, Cynata Enters Agreement for Strategic Alliance in Japan.

Omniblend Innovation identifies China as key market

Arie Nudel, Managing Director of Melbourne-based Omniblend Innovation, identified China has a key market for its company’s innovative product GlucoControl, a pre-drink meal that assists diabetes sufferers. Omniblend launched the product in Australia and sought negotiations with China and Hong Kong.

Read the article, Australian-developed GlucoControl slows rapid growth of diabetes, from The Australian.

The Burnet Institute and Nanjing Biopoint Diagnostic Technology

The Burnet Institute established commercial company Nanjing BioPoint Diagnostic Technology in China, with a plan to expand its China program and develop diagnostic tools in areas of unmet medical need.

Read the case study in the Guide for Australian Medical technology companies seeking to engage in China (the China Guide) from AusBiotech. 

Tweets by @AusBiotech